H2020Обмен на изследователи2019–2024

INNOVA4TB · Innovation in Tuberculosis

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2019-01-01 → 2024-06-30
Финансиране от ЕС: 1 039 600 €
Участници: 16
Схема: MSCA-RISE

Линиите свързват координатора с партньорите.

Накратко на български

Нови методи за диагностика и персонализирано лечение на туберкулозата, например чрез анализ на кръв и рентгенови маркери, се разработват в проекта. Това помага за по-точно определяне на продължителността на терапията и намаляване на страничните ефекти при пациентите.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Innovation in Tuberculosis

The incidence of tuberculosis (TB) is still high in several countries, and it is one of the major infectious diseases worldwide. The emergence and spread of multi-drug and extensive resistant cases is a public health threat. In addition, the armed conflicts that is experiencing Europe, and other part of the world, have provoked a large number of refugees and displaced population. However, the conventional methods used for diagnosis and drug-susceptibility testing are not enough for controlling the disease. In addition, all TB patients, independently of their age, gender, severity of the disease and type of responsible strain, follow the same treatment duration, which often leads to high frequency of adverse events, suboptimal adherence to treatment, and poor outcome. A progressive transition from programmatic to personalized management of TB is needed. Our proposal has developed innovative technologies and approaches in order to improve the individual risk assessment for TB development if the patient is infected; to rapidly diagnose active TB using new methods applied to non-sputum samples; to detect the drug susceptibility of the strain using molecular methods; to design tailor-made therapies including the exploration of new molecules and new ways of delivery; and to use blood and X-ray biomarkers to guide and individualize the duration of antimicrobial therapy. All these achievements are of great importance for improving the quality of life of patients and ensuring treatment success, as well as for economic reasons for the healthcare system. The overall objective of INNOVA4TB was to enhance and strengthen the collaborative research among sectors and to form a network aimed to perform high-quality and translational research in the field of diagnosis and management of TB. The consortium is constituted by 16 institutions from 8 countries that combined complementary and synergic expertise: clinical management (hospitals), basic science and new technologies (academic institutions), and industrial development and entrepreneurship culture (SMEs). The exchanges between the institutions have allowed the participants to progress in their career perspectives.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The objective of INNOVA4TB is to enhance and strengthen the collaborative research among sectors and to form a network aimed to perform high-quality and translational research in the field of diagnosis and management of tuberculosis (TB). The consortium is constituted by 12 institutions from 8 countries that combine complementary and synergic expertise: clinical management (hospitals), basic science and new technologies (academic institutions), and industrial development and entrepreneurship culture (SMEs). The exchanges between the institutions allow the participants to progress in their career perspectives.TB is one of the major infectious diseases worldwide, and the emergence and spread of drug resistant cases is a public health threat. However, the conventional methods used for diagnosis and drug-susceptibility testing are not enough for controlling the disease. In addition, all TB patients, independently of their age, gender, severity of the disease and type of responsible strain, follow the same treatment duration (up to 20 months in drug resistant cases), which often leads to high frequency of adverse events, suboptimal adherence to treatment, and poor outcome. A transition from programmatic to personalized management of TB is needed. Our proposal will develop innovative technologies and approaches in order to improve the individual risk assessment for TB development, to rapidly diagnose active TB, to detect the drug susceptibility of the strain, to design tailor-made therapies, and to use biomarkers to guide and individualize the duration of antimicrobial therapy. This is of great importance for improving the quality of life of patients and ensuring treatment success, as well as for economic reasons for the healthcare system.

Оригинален текст от CORDIS (на английски).

Участници

INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL · Badalona BarcelonaКоординаторИспания
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE · San SebastianИспания
CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. · MadridИспания
EMPE DIAGNOSTICS AB · StockholmШвеция
Genome Identification Diagnostics GmbH · StrassbergГермания
INSTITUTIA MEDICO-SANITARA PUBLICA - INSTITUTUL DE PNEUMOLOGIE ""CHIRIL DRAGANIUC"""" · CHISINAUМолдова
INSTITUTO ARAGONES DE CIENCIAS DE LA SALUD · ZARAGOZAИспания
KOMUNALNE NEKOMERSHCHYNE PRIDPRYEMSTVO ODESKYY OBLASNYY TSENTR SOTSIALNO ZNACHUCHYKH KHVOROB ODESKOI OBLASNOY RADY · OdesaУкрайна
MAGRITEK GMBH · AachenГермания
ODESKIY NACIONALNIY UNIVERSITET IMENI I.I. MECHNIKOVA · OdessaУкрайна
SERVICIOS CLINICOS SA · BarcelonaИспания
UMEA UNIVERSITET · UMEAШвеция
UNIVERSIDAD DE LA FRONTERA · TemucoЧили
UNIVERSIDAD DE ZARAGOZA · ZaragozaИспания
UNIVERSIDAD POLITECNICA DE MADRID · MadridИспания
VINNYTSIA NATIONAL M.I. PYROGOV MEDICAL UNIVERSITY · VinnitsaУкрайна